Induction of therapeutic antibodies by vaccination against external loops of tumor-associated viral latent membrane protein

Journal of Virology

Volumn 83, Issue 22, 2009, Pages 11734-11745

  Delbende, Catherine ^a,b   Verwaerde, Claudie ^b   Mougel, Alexandra ^b   Bunel, Denis Tranchand ^b,c  

^a UNIV LILLE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; LATENT MEMBRANE PROTEIN 1; LEUCYLTRYPTOPHYLASPARAGINYLLEUCYLHISTIDYLGLYCYLGLUTAMINYL ALANYLLEUCYLCYSTEINYLLEUCYLTYROSYLLEUCYLGLUTAMINYLGLUTAMINYL ASPARAGINYLTRYPTOPHYLTRYPTOPHYLTHREONINE; METHIONYLSERYLASPARTYLTRYPTOPHYLTHREONYLGLYCYLGLYCYL ALANYLLEUCYLCYSTEINYLLEUCYLTYROSYLLEUCYLGLUTAMINYLGLUTAMINYL ASPARAGINYLTRYPTOPHYLTRYPTOPHYLTHREONINE; METHIONYLSERYLASPARTYLTRYPTOPHYLTHREONYLGLYCYLGLYCYLALANYLLEUCYL CYSTEINYLLEUCYLTRYPTOPHYLASPARAGINYLLEUCYLHISTIDYLGLYCYLGLUTAMINYLALANYLLEUCINE; PEPTIDE ANTIBODY; THREONYLTRYPTOPHYLARGINYLISOLEUCYLGLUTAMYLASPARTYLPROLYL PROLYLPHENYLALANYLASPARAGINYLSERYLLEUCYLCYSTEINYLVALYLASPARTYL ALANYLVALYLLEUCYLGLUTAMINYLLEUCYLSERYLPROLYLLEUCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNIZATION; CANCER PREVENTION; CELL SURFACE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRUS CARCINOGENESIS; XENOGRAFT;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS VACCINES; HUMANS; MICE; MICE, INBRED BALB C; VACCINATION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4; MUS;

EID: 70350327339     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00578-09     Document Type: Article

References (39)

1. Beisser, P. S., L. Laurent, J. L. Virelizier, and S. Michelson. 2001. Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. J. Virol. 75:5949-5957.
2. Bernstein, D. I. 2001. Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 8:8-11. (Pubitemid 32290372)
3. Brinkmann, M. M., and T. F. Schulz. 2006. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gamma-herpesvirinae. J. Gen. Virol. 87:1047-1074.
4. Burton, D. R. 2002. Antibodies, viruses and vaccines. Nat. Rev. 2:706-713.
5. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6:343-357.
6. Chan, W., and P. D. White. 2000. Fmoc solid phase peptide synthesis, p. 9-40. In B. D. Hames (ed.), Peptide synthesis: a practical approach. Oxford University Press, Oxford, United Kingdom.
7. Chien, Y. C., J. Y. Chen, M. Y. Liu, H. I. Yang, M. M. Hsu, C. J. Chen, and C. S. Yang. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345:1877-1882.
8. Couty, J. P., and M. C. Gershengorn. 2005. G-protein-coupled receptors encoded by human herpesviruses. Trends Pharmacol. Sci. 26:405-411.
9. Friguet, B., B. F. Chaffotte, L. Djavadi-Ohaniance, and M. E. Goldberg. 1995. Under proper experimental conditions the solid-phase antigen does not disrupt the liquid phase equilibrium when measuring dissociation constants by competition ELISA. J. Immunol. Methods 182:145-150.
10. Fruehling, S., S. K. Lee, R. Herrold, B. Frech, G. Laux, E. Kremmer, F. A. Grasser, and R. Longnecker. 1996. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J. Virol. 70:6216-6226. (Pubitemid 26266840)
11. International Agency for Research on Cancer. 1997. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC Monogr. Eval. Carcinog. Risks Hum. 70:1-492.
12. Johnson, Z., M. Schwarz, C. A. Power, T. N. Wells, and A. E. Proudfoot. 2005. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol. 26:268-274. (Pubitemid 41556850)
13. Klein, M., A. Kotz, K. Bernardo, and M. Kronke. 2003. Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein. J. Clin. Microbiol. 41:1957-1962.
14. Landolfo, S., M. Gariglio, G. Gribaudo, and D. Lembo. 2003. The human cytomegalovirus. Pharmacol. Ther. 98:269-297.
15. Liebowitz, D., D. Wang, and E. Kieff. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:233-237. (Pubitemid 16021984)
16. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55:710-720.
17. Marshall, N. A., M. A. Vickers, and R. N. Barker. 2003. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J. Immunol. 170:6183-6189.
18. Masy, E., E. Adriaenssens, C. Montpellier, et al. 2002. Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation. J. Virol. 76:6460-6472. (Pubitemid 34633511)
19. McLean, K. A., P. J. Holst, L. Martini, T. W. Schwartz, and M. M. Rosenkilde. 2004. Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. Virology 325:241-251.
20. Meij, P., M. B. Vervoort, C. J. Meijer, E. Bloemena, and J. M. Middeldorp. 2000. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J. Virol. Methods 90:193-204. (Pubitemid 30813372)
21. Meij, P., A. Leen, A. B. Rickinson, S. Verkoeijen, M. B. Vervoort, E. Bloemena, and J. M. Middeldorp. 2002. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int. J. Cancer 99:93-99. (Pubitemid 34273204)
22. Middeldorp, J. M., A. A. Brink, A. J. van den Brule, and C. J. Meijer. 2003. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit. Rev. Oncol. Hematol. 45:1-36.
23. Miranda, L. P., and P. F. Alewood. 1999. Accelerated chemical synthesis of peptides and small proteins. Proc. Natl. Acad. Sci. USA 96:1181-1186.
24. Mitchell, D. A., W. Xie, R. Schmittling, C. Learn, A. Friedman, R. E. McLendon, and J. H. Sampson. 2008. Sensitive detection of human cytomegalovirus in tumours and peripheral blood of patients diagnosed with glioblastoma. Neurol. Oncol. 10:10-18.
25. Nanni, P., L. Landuzzi, G. Nicoletti, et al. 2004. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol. 173:2288-2296. (Pubitemid 39063084)
26. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510-1512. (Pubitemid 41746349)
27. Polyak, M. J., and J. P. Deans. 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99:3256-3262.
28. Rosenkilde, M. M., and T. N. Kledal. 2006. Targeting herpesvirus reliance of the chemokine system. Curr. Drug Targets 7:103-118.
29. Rowe, M., H. S. Evans, L. S. Young, K. Hennessy, E. Kieff, and A. B. Rickinson. 1987. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68:1575-1586.
30. Sharp, T. V., H. W. Wang, A. Koumi, D. Hollyman, Y. Endo, H. Ye, M. Q. Du, and C. Boshoff. 2002. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J. Virol. 76:802-816.
31. Sodhi, A., S. Montaner, and J. S. Gutkind. 2004. Viral hijacking of G-protein-coupled-receptor signalling networks. Nat. Rev. Mol. Cell Biol. 5:998-1012.
32. Thorley-Lawson, D. A., L. Chess, and J. L. Strominger. 1977. Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J. Exp. Med. 146:495-508.
33. Tranchand Bunel, D., H. Gras-Masse, B. Bourez, L. Dedecker, and C. Auriault. 1999. Evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay using a synthetic convergent peptide library, or mixotope, for diagnosis of primary EBV infection. J. Clin. Microbiol. 37:2366-2368.
34. Tranchand Bunel, D. 2004. Abstr. 11th Int. EBV Symp., Regensburg, Germany, 20 to 25 September 2004, abstr. 15.05.
35. Vischer, H. F., R. Leurs, and M. J. Smit. 2006. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signalling networks. Trends Pharmacol. Sci. 27:56-63.
36. Vischer, H. F., J. W. Hulshof, I. J. de Esch, M. J. Smit, and R. Leurs. 2006. Virus-encoded G-protein-coupled receptors: constitutively active (dys)regulators of cell function and their potential as drug target. Ernst. Schering Found. Symp. Proc. 2:187-209.
37. Wong, M. M., and N. E. Fish. 2003. Chemokines: attractive mediators of the immune response. Semin. Immunol. 15:5-14.
38. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768.
39. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5:263-274.